Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Shenzhen Neptunus Interlong Bio-technique Co Ltd

8329:HKG.HZ

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Actions
  • Price (HKD)0.136
  • Today's Change0.007 / 5.43%
  • Shares traded130.00k
  • 1 Year change-0.73%
  • Beta--
Data delayed at least 15 minutes, as of Nov 04 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shenzhen Neptunus Interlong Bio-Technique Company Limited is a Hong Kong-based company principally engaged in the development, production and sales of medicines. The Company operates through three segments. Medicines segment is engaged in the manufacture and sales of medicines. Medicines and Healthcare Products segment is engaged in the sales and distribution of medicines and healthcare products. Research and Development Services of Modern Biological Technology segment is engaged in the provision of research and development services of modern biological technologies, such as in vitro diagnostics reagents businesses. The products of the Company include herbal medicines, generic drugs, transfusion and anti-tumor drugs, among others. The Company mainly operates businesses in China.

  • Revenue in HKD (TTM)1.15bn
  • Net income in HKD35.11m
  • Incorporated1994
  • Employees1.47k
  • Location
    Shenzhen Neptunus Interlong Bio-technique Co Ltd1F, Block 1, Research BuildingNeptunus Technical CenterSHENZHEN 518000ChinaCHN
  • Phone+86 75 526411869
  • Fax+86 75 586391610
  • Websitehttps://www.interlong.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.